Complete atrioventricular block associated with rivastigmine therapy

American Journal of Health-System Pharmacy

Volumn 65, Issue 11, 2008, Pages 1051-1053

  Kayrak, Mehmet ^a   Yazici, Mehmet ^a   Ayhan, Selim S ^a   Koc, Fatih ^a   Ulgen, Mehmet S ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Alzheimer disease; Amlodipine; Atrioventricular block; Drugs, adverse reactions; Geriatrics; Nateglinide; Pacemakers; Parasympathomimetic agents; Rivastigmine

Indexed keywords

AMLODIPINE; NATEGLINIDE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ANGIOCARDIOGRAPHY; ARTICLE; ATRIOVENTRICULAR BLOCK; CASE REPORT; DIABETES MELLITUS; DIZZINESS; ECHOCARDIOGRAPHY; ELECTROLYTE BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; PACEMAKER; PRIORITY JOURNAL; SYNCOPE;

EID: 44449136502     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070230     Document Type: Article

References (11)

1. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998; 20:634-47.
2. Enz A, Boddeke H, Gray J et al. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Ann N Y Acad Sci. 1991; 640:272-5.
3. Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer's disease. Drugs. 2001; 61:41-52.
4. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
5. Savci V, Gürün MS, Cavun S et al. Cardiovascular effects of centrally injected tetrahidroaminoacridine in conscious normotensive rats. Eur J Pharmacol. 1998; 346:35-41.
6. Calvo-Romero JM, Ramos-Salado JL. [Symptomatic sinus bradycardia associated with donepezil.] Rev Neurol. 1999; 28:1070-2. In Spanish.
7. Bordier P, Garrigue S, Barold SS et al. Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors. Europace. 2003; 5:429-31.
8. Leentjens AF, Kragten JA. [Complete atrioventricular block during galantamine therapy.] Ned Tijdschr Geneeskd. 2006; 150:563-6. In Dutch.
9. Giacobini E. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging. 2001; 18:891-8.
10. Morganroth J, Graham S, Hartman R et al. Electrocardiographic effects of rivastigmine. J Clin Pharmacol. 2002; 42:558-68.
11. Blesa R, Bullock R, He Y et al. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genomics. 2006; 16:771-4.